FEDERAL HOUSING FINANCE BOARD

Announcing an Open Meeting of the Board

TIME AND DATE: 10 a.m., Wednesday, November 14, 2001.

PLACE: Board Room, Second Floor, Federal Housing Finance Board 1777 F Street, NW., Washington, DC 20006.

STATUS: The entire meeting will be open to the public.

MATTERS TO BE CONSIDERED DURING PORTIONS OPEN TO THE PUBLIC:

- Final Rule: Unsecured Credit Limits for the Federal Home Loan Banks.
- Proposed Rule: Amendments to the Affordable Housing Program.

CONTACT PERSON FOR MORE INFORMATION: Elaine L. Baker, Secretary to the Board, (202) 408–2837.

James L. Bothwell,

Managing Director.

[FR Doc. 01–28411 Filed 11–7–01; 2:48 pm]

BILLING CODE 6725–01–P

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090–0204]

Submission for OMB Review; Comment Request Entitled Commercial Delivery Schedule Clause and Notice of Shipment

AGENCY: Office of Acquisition Policy, GSA.

ACTION: Notice of a request for extension of the reinstated collection (3090–0204).

SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the General Services Administration (GSA) has submitted to the Office of Management and Budget (OMB) a request to review and approve an information collection requirement concerning the Commercial Delivery Schedule (Multiple Award Schedule) clause and the Notice of Shipment clause. OMB reinstated the collection on July 20, 2001. Information collected under this authority is not otherwise required by regulation. A request for public comments was published at 66 FR 42864, August 15, 2001. No comments were received.

DATES: Comments may be submitted on or before December 10, 2001.

FOR FURTHER INFORMATION CONTACT: Beverly Cromer, Office of GSA Acquisition Policy (202) 501–1224.

ADDRESSES: Comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, should be submitted to: Ed Springer, GSA Desk Officer, OMB, Room 10236, NEOB, Washington, DC 20503, and a copy to Stephanie Morris, General Services Administration, Acquisition Policy Division, 1800 F Street, NW, Room 4035, Washington, DC 20405.

SUPPLEMENTARY INFORMATION:

A. Purpose

The GSA is requesting the Office of Management and Budget (OMB) to review and approve information collection, 3090–0204, concerning the Commercial Delivery Schedule (Multiple Award Schedule) clause. The Commercial Delivery Schedule (Multiple Award Schedule) clause required offerors to provide their commercial delivery terms and conditions. FSS awards contracts to commercial firms under terms and conditions that mirror commercial practices for the supplies and services. In order to ensure the Government obtains the supplies within the offeror's commercial delivery timeframe, the offeror must provide the information requested in the clause, Commercial Delivery Schedule (Multiple Award Schedule).

The GSA is requesting the Office of Management and Budget (OMB) to review and approve information collection, 3090–0204, concerning the Notice of Shipment clause. A Notice of Shipment clause is used when it is in the Government's interest to have a supply contractor furnish a notice of shipment. Such a notice is necessary when preparations need to be made for docking arrangements, storage, trans-shipment of materials handling equipment of supplies and equipment open delivery, labor and inside delivery at destination.

B. Annual Reporting Burden

Number of Respondents: 4109.
Total Annual Responses: 10,305.
Total Burden Hours: 2669.

Obtaining Copies of Proposals

Requester may obtain a copy of the proposal from the General Services Administration, Regulatory Secretariat (MVP), 1800 F Street, NW, Room 4035, Washington, DC 20405, telephone (202) 501–4755. Please cite OMB Control No. 3090–0204, Commercial Delivery Schedule (Multiple Award Schedule) clause and Notice of Shipment clause.

Dated: November 1, 2001.

Al Matera,

Director, Acquisition Policy Division.

[FR Doc. 01–28121 Filed 11–8–01; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 02006]

Epidemiologic Studies of Reproductive and Developmental Outcomes—Denmark; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2002 funds for a cooperative agreement program for Epidemiologic Studies of Reproductive and Developmental Outcomes. This program addresses the ''Healthy People 2010'' focus area Maternal, Infant, and Child Health.

The purpose of the program is to investigate risk factors for poor reproductive and developmental outcomes including, but not limited to, autism, cerebral palsy, and fetal alcohol effects. Important risk factors include, but may not be limited to, adverse intrauterine exposures such as infection, alcohol and genetic conditions.

B. Eligible Applicants

Assistance will be provided only to the Danish Medical Research Council (DMRC), in the Danish Ministry of Information Technology and Research. No other applications are solicited.

Denmark has a singular combination of national public health data systems currently in place that are not found elsewhere in the U.S. or abroad. These data systems are developed and maintained by the Danish government/DMRC which is solely responsible for granting access to them. In the Danish government, the DMRC represents the most comprehensive scientific knowledge in Danish medical research and is responsible for providing financial and advisory support for medical research in Denmark. Among its supportive functions, the DMRC is responsible for promoting significant research tasks, especially in areas where the Danish research environment has special qualifications (such as the national data systems), and international research cooperation. This program falls within the jurisdiction of the DMRC.

The unique combination of Danish data systems includes nearly 200 long-established national disease and administrative registries and a long-established national biobank of archived newborn blood samples. Many of these data systems have been established for

several decades and have national coverage, thereby including information on thousands of individuals over time. These systems are regularly accessed by researchers to investigate a variety of health issues such as time trends in disease or disease characteristics that require large data bases. The data systems also include the Danish National Birth Cohort (DNBC) of 100,000 pregnant women and their children. The DNBC is uniquely conducting serial biosampling of the mother and newborn (to be archived in a biobank) and serial interviews of the mother concerning her health and behavior during pregnancy and postnatal development of her child. This unique combination of Danish data systems, that can be readily linked by a universal personal identifier, provides the necessary information (such as health, medical, and sociodemographic information) to carry out this program. Also, because these data systems contain information on large numbers of individuals over long periods of time, studies of relatively rare outcomes, such as autism and cerebral palsy, can be made with an unusually high level of statistical power.

Note: Title 2 of the United States Code, section 1611 states that an organization described in section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.

C. Availability of Funds

Approximately $580,000 is available in FY 2002 to fund this award. It is expected that the award will begin on or about February 1, 2002, and will be made for a 12-month budget period within a project period of up to three years. Funding estimates may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

D. Program Requirements

In conducting activities to achieve the purpose of this program, the recipient will be responsible for the activities under 1. (Recipient Activities), and CDC will be responsible for the activities listed under 2. (CDC Activities).

1. Recipient Activities

a. Develop and implement epidemiologic studies of reproductive and developmental outcomes. The studies could include, but may not be limited to, (1) evaluation of pre-, peri-, and postnatal risk factors, including genetic factors and environmental exposures, and (2) identification of biomarkers.

b. Disseminate the findings in the form of reports, presentations to public and professional audiences, and published manuscripts.

2. CDC Activities

a. Provide, if requested, epidemiologic, statistical, and technical assistance throughout the study including development and implementation of studies.

b. Assist in the development of a research protocol for Institutional Review Board (IRB) review by all cooperating institutions participating in the research project. The CDC IRB will review and approve the protocol initially and on at least an annual basis until the research project is completed.

E. Application Content

Use the information in the Program Requirements, Other Requirements, and Evaluation Criteria sections to develop the application content. The application will be evaluated on the criteria listed, so it is important to follow them in laying out the program plan. The narrative should be no more than 25 single-spaced pages, printed on one side, with one inch margins, and unreduced font.

F. Submission and Deadline

Submit the original and five copies of PHS–398 (OMB Number 0925–0001) (adhere to the instructions on the Errata Instruction Sheet for PHS 398). Forms are available in the application kit and at the following Internet address: *www.cdc.gov/od/pgo/forminfo.htm*

On or before December 1, 2001, submit the application to the Grants Management Specialist identified in the ''Where to Obtain Additional Information'' section of this announcement.

Deadline: The application shall be considered as meeting the deadline if they are either:

1. Received on or before the deadline date; or

2. Sent on or before the deadline date and received in time for submission to the independent review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late: Applications which do not meet the criteria in 1. or 2. above will be returned to the applicant.

G. Evaluation Criteria

The application will be evaluated individually against the following criteria by an independent review group appointed by CDC.

1. Understanding the Problem (20 Points)

a. Extent to which applicant has a clear understanding of the requirements and purpose of the cooperative agreement.

b. Extent to which applicant understands the issues and challenges associated with developing and implementing epidemiologic studies of reproductive and developmental outcomes.

2. Goals and Objectives (20 Points)

a. Extent to which applicant clearly describes the goals and objectives of the project.

b. Extent to which applicant's goals and objectives are consistent with the stated goals and purpose of this announcement.

c. The degree to which the applicant has met the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes:

(1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation.

(2) The proposed justification when representation is limited or absent.

(3) A statement as to whether the design of the study is adequate to measure differences when warranted.

(4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits.

3. Description of Program and Methodology (40 Points)

Extent to which applicant describes the studies' methods including:

a. Study hypotheses and design,

b. Target population,

c. Relevant data sources and linkages,

d. Data base assembly,

e. Laboratory methods (where applicable), and

f. analytic approach.

4. Evaluation Plan (10 Points)

Extent to which applicant describes an evaluation plan that will monitor reliability, progress, timeliness, and completeness of the objectives and activities of the project.

5. Staffing and Management System (10 Points)

a. Extent to which key personnel have the qualifications, skills, and experience in epidemiologic and laboratory methods, data management, and analysis to develop and implement analytic studies of reproductive and developmental outcomes.

b. Extent to which the applicant has the ability to manage and coordinate the project.

c. Extent to which there is appropriate dedicated staff time to develop and implement the project.

d. Extent to which the applicant provides an appropriate time line and includes activities and personnel responsibilities.

e. Extent to which the applicant demonstrates an organizational structure (include an organizational chart) and facilities/space/equipment that are adequate to carry out the activities of the program.

6. Human Subjects Review (Not Scored).

The extent to which the applicant complies with 45 CFR Part 46 for the protection of human subjects.

7. Budget (Not Scored).

The extent to which the budget is reasonable, clearly justified, and consistent with the intended use of funds.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of—

1. Annual progress reports (English language only);

2. Financial status report, no more than 90 days after the end of the budget period (in US Dollars); and

3. Final financial and performance reports, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the ''Where to Obtain Additional Information'' section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I of the announcement in the application kit.

AR–1 Human Subjects Requirements
AR–2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
AR–9 Paperwork Reduction Act Requirements
AR–10 Smoke-Free Workplace Requirements
AR–11 Healthy People 2010
AR–12 Lobbying Restrictions
AR–22 Research Integrity

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under section 307 of the Public Health Service Act, [42 U.S.C. section 2421], as amended. The Catalog of Federal Domestic Assistance number is 93.184.

J. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—*http://www.cdc.gov.* Click on ''Funding'' then ''Grants and Cooperative Agreements.''

To obtain business management technical assistance, contact: Nancy Pillar, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, Announcement 02006, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone number: 770–488–2716, Email: *nfp6@cdc.gov.*

For program technical assistance, contact: Diana Schendel, Ph.D., Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 4770 Buford Highway, Mail Stop F–15, Atlanta, Georgia 30341, Telephone number: 770–488–7359, Email: *dcs6@cdc.gov.*

Dated: November 5, 2001.

Rebecca O'Kelley,

Acting Chief, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01–28148 Filed 11–8–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Cooperative Research and Development Agreement (CRADA)

AGENCY: Centers for Disease Control and Prevention (CDC), Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC) is seeking a CRADA partner(s) for collaboration to utilize the newly acquired knowledge that the CX3C chemokine region in the respiratory syncytial virus (RSV) G glycoprotein binds to the chemokine receptor CX3CR1 and this binding facilitates RSV infection of cells and induces chemokine-like responses to develop ways to treat or prevent RSV disease. The CRADA partner could be involved in all or part of studies examining (1) alteration of the CX3C region in the G glycoprotein of live viruses in such a way as prevent CX3C interaction with the CX3C receptor (CX3CR1) on cells and improve the safety and/or efficacy of a live virus vaccine; (2) alteration of the G glycoprotein to enhance induction of antibodies that block G glycoprotein binding to the CX3C chemokine receptor, CX3CR1, and treat or prevent RSV disease; (3) development of reagents (drugs, antibodies, peptides, polypeptides, etc.) that block interaction of the CX3C region in G glycoprotein with CX3CR1 on cells to treat or prevent RSV disease; (4) development of assays to detect blocking of G glycoprotein binding to the CX3C receptor, CX3CR1, or detect blocking of the biological activity initiated by G glycoprotein binding to CX3CR1 to identify reagents (drugs, antibodies, peptides, polypeptides, etc.) or evaluate candidate vaccines that might be used as prophylactic or therapeutic treatments for preventing RSV disease.

Because CRADAs are designed to facilitate the development of scientific and technological knowledge into useful, marketable products, a great deal of freedom is given to Federal agencies in implementing collaborative research. The CDC may accept staff, facilities, equipment, supplies, and money from the other participants in a CRADA; CDC may provide staff, facilities, equipment, and supplies to the project. There is a single restriction in this exchange: CDC MAY NOT PROVIDE FUNDS to the other participants in a CRADA.

DATES: This opportunity is available until December 10, 2001. Respondents may be provided a longer period of time to furnish additional information if CDC finds this necessary.

ADDRESSES: The responses must be made to: Lisa Blake-DiSpigna, Technology Development Coordinator, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE., Mailstop C–19, Atlanta, GA 30333.

FOR FURTHER INFORMATION CONTACT:

Technical: Ralph A. Tripp, Ph.D., Respiratory and Enteric Viruses, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE., Mailstop G–09, Atlanta, GA 30333, telephone (404) 639–3427.

Business: Lisa Blake-DiSpigna, Technology Development